Twist Bioscience Corporation logo TWST - Twist Bioscience Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 1
SELL 1
STRONG
SELL 0
| PRICE TARGET: $64.40 DETAILS
HIGH: $80.00
LOW: $52.00
MEDIAN: $65.00
CONSENSUS: $64.40
UPSIDE: 6.32%

Stock News

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

May 08, 2026 05:08 AM • businesswire.com
Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.

May 07, 2026 05:45 AM • seekingalpha.com
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.

May 05, 2026 04:00 AM • businesswire.com
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes. “As research in nucleic acid therapeutics and AI-guided protein design and therapeutics discovery accelerate, scientists need a reliable partner to consistently deliver genes rapidly at scale and with more complex sequences,” said Emily M. Leproust, Ph.D., CEO and co-founder.

May 04, 2026 03:20 AM • businesswire.com
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2026 earnings report and the investor presentation, or click https://investors.tw.

May 04, 2026 03:15 AM • businesswire.com
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 second quarter ended March 31, 2026, before the opening of the market on May 4, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business.

Apr 21, 2026 04:00 AM • businesswire.com
Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Analysts

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price

Apr 03, 2026 12:43 AM • defenseworld.net
Zenas BioPharma (NASDAQ:ZBIO) versus Twist Bioscience (NASDAQ:TWST) Critical Analysis

Zenas BioPharma (NASDAQ:ZBIO) versus Twist Bioscience (NASDAQ:TWST) Critical Analysis

Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability. Analyst Ratings This is a summary of current

Mar 27, 2026 09:28 PM • defenseworld.net
Artisan Partners Limited Partnership Grows Stake in Twist Bioscience Corporation $TWST

Artisan Partners Limited Partnership Grows Stake in Twist Bioscience Corporation $TWST

Artisan Partners Limited Partnership boosted its stake in Twist Bioscience Corporation (NASDAQ: TWST) by 26.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,410,900 shares of the company's stock after buying an additional 1,349,867 shares during the quarter. Artisan Partners

Feb 26, 2026 10:26 PM • defenseworld.net

Price Targets